Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Publication year range
1.
Sci Rep ; 9(1): 16905, 2019 11 15.
Article in English | MEDLINE | ID: mdl-31729441

ABSTRACT

Invasive candidiasis is an increasingly frequent cause of serious and often fatal infections in hospitalized and immunosuppressed patients. Mortality rates associated with these infections have risen sharply due to the emergence of multidrug resistant (MDR) strains of C. albicans and other Candida spp., highlighting the urgent need of new antifungal therapies. Rhesus theta (θ) defensin-1 (RTD-1), a natural macrocyclic antimicrobial peptide, was recently shown to be rapidly fungicidal against clinical isolates of MDR C. albicans in vitro. Here we found that RTD-1 was rapidly fungicidal against blastospores of fluconazole/caspofungin resistant C. albicans strains, and was active against established C. albicans biofilms in vitro. In vivo, systemic administration of RTD-1, initiated at the time of infection or 24 h post-infection, promoted long term survival in candidemic mice whether infected with drug-sensitive or MDR strains of C. albicans. RTD-1 induced an early (4 h post treatment) increase in neutrophils in naive and infected mice. In vivo efficacy was associated with fungal clearance, restoration of dysregulated inflammatory cytokines including TNF-α, IL-1ß, IL-6, IL-10, and IL-17, and homeostatic reduction in numbers of circulating neutrophils and monocytes. Because these effects occurred using peptide doses that produced maximal plasma concentrations (Cmax) of less than 1% of RTD-1 levels required for in vitro antifungal activity in 50% mouse serum, while inducing a transient neutrophilia, we suggest that RTD-1 mediates its antifungal effects in vivo by host directed mechanisms rather than direct fungicidal activity. Results of this study suggest that θ-defensins represent a new class of host-directed compounds for treatment of disseminated candidiasis.


Subject(s)
Candidiasis/drug therapy , Candidiasis/mortality , Defensins/therapeutic use , Animals , Biofilms/drug effects , Candida albicans/drug effects , Candida albicans/physiology , Candidiasis/immunology , Candidiasis/metabolism , Defensins/pharmacokinetics , Drug Resistance, Multiple/drug effects , Drug Resistance, Multiple, Fungal/drug effects , Female , Host-Pathogen Interactions/drug effects , Host-Pathogen Interactions/immunology , Macaca mulatta/immunology , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests , Signal Transduction/drug effects , Signal Transduction/immunology , Survival Analysis
2.
Endocrinol. nutr. (Ed. impr.) ; 63(2): 87-94, feb. 2016. tab, graf
Article in Spanish | IBECS | ID: ibc-148491

ABSTRACT

El calcitriol ha sido considerado durante años exclusivamente como una hormona reguladora del metabolismo fosfocálcico, pero últimamente se ha demostrado que numerosas células implicadas en la inmunidad innata (epitelios de barrera, monocitos/macrófagos, etc.) son capaces de reconocer determinadas moléculas repetitivas características de diversos gérmenes patógenos mediante receptores de membrana o intranucleares. La activación de estos receptores induce la síntesis de la 1α-hidroxilasa, con lo que dichas células son capaces de sintetizar calcitriol a partir de la 25 hidroxivitamina D circulante. El calcitriol, a través del receptor la vitamina D, modula la expresión de determinados péptidos antimicrobianos, como la catelicidina, la β2-defensina o la hepcidina. Estos péptidos representan un mecanismo versátil de la lucha antibacteriana innata y su producción se ve alterada en la hipovitaminosis D. Se realiza un análisis de la literatura sobre sus mecanismos de secreción, las concentraciones en diversos líquidos orgánicos, y los mecanismos de acción y su relación con la vitamina D (AU)


Traditionally, calcitriol has been considered a calcium and phosphate regulating hormone, but has recently been shown to play a pivotal role in innate immunity. Many barrier and immune cells have membrane and intracellular receptors that recognize different microbial antigens. Activation of these receptors induces synthesis of 1α-hydroxylase, which acts on 25 hydroxyvitamin D to generate intracellular calcitriol. Calcitriol activates its receptor and enhances the synthesis of important human antibiotics like cathelicidin and β2-defensin while inhibiting hepcidin. These pluripotent peptides have an important role in innate immunity, and their regulation is abnormal in hypovitaminosis D. The literature on their secretion mechanisms, levels in different organic fluids, mechanism of action, and relationship with vitamin D is reviewed here (AU)


Subject(s)
Humans , Vitamin D Deficiency/physiopathology , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/pharmacokinetics , Cathelicidins/pharmacokinetics , Defensins/pharmacokinetics , Hepcidins/pharmacokinetics , Calcitriol/pharmacokinetics
3.
Am J Pathol ; 172(3): 702-13, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18258845

ABSTRACT

Human defensin (HD)-5 is an antimicrobial peptide expressed in small intestinal Paneth cells, and alterations in HD-5 expression may be important in Crohn's disease (CD) pathogenesis. Levels of HD-5 in Paneth cells and ileostomy fluid from control and CD patients were studied by quantitative immunodot analysis, immunohistochemistry, acid urea-polyacrylamide gel electrophoresis and sodium dodecyl sulfate-polyacrylamide gel electrophoresis Western blotting, reverse phase-high performance liquid chromatography, N-terminal amino acid sequencing, and ES-QToF mass spectrometry. In both control and CD patients, HD-5 in Paneth cell extracts was present almost exclusively in the precursor form. HD-5 levels in ileostomy fluid were lower in CD patients (n = 51) than in controls (n = 20): median (range), 7.9 (5.5 to 35.0) microg/ml versus 10.5 (6.0 to 30.4) microg/ml; P = 0.05; this difference was most marked in CD patients with homozygous/compound heterozygous mutations in NOD2 (P = 0.03). In control ileostomy fluid, HD-5 was present in the mature form only. In contrast, CD patient ileostomy fluid contained both precursor and mature forms of HD-5, with the majority present in a complex with trypsin, chymotrypsinogen/chymotrypsin, and alpha1-anti-trypsin. Pro-HD-5 was not associated with trypsin or chymotrypsinogen in Paneth cell extracts. In conclusion, pro-HD-5 in the intestinal lumen is processed by trypsin in a complex in which chymotrypsinogen is also cleaved for activation. The persistence of this complex in CD may be attributable to increased luminal levels of proteinase inhibitors such as alpha1-anti-trypsin.


Subject(s)
Chymotrypsinogen/metabolism , Crohn Disease/metabolism , Defensins/metabolism , Intestinal Mucosa/metabolism , Protein Processing, Post-Translational , Trypsin/metabolism , alpha-Defensins/metabolism , Adult , Amino Acid Sequence , Body Fluids/chemistry , Body Fluids/metabolism , Case-Control Studies , Chromatography, High Pressure Liquid , Defensins/pharmacokinetics , Female , Humans , Ileostomy , Intestine, Small/metabolism , Male , Middle Aged , Models, Biological , Molecular Sequence Data , Multiprotein Complexes/metabolism , Protein Precursors/metabolism , Tissue Extracts/metabolism , alpha 1-Antitrypsin/metabolism , alpha-Defensins/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL